Court keeps mifepristone mail access

A federal judge in Louisiana did not stop abortion pills from being mailed this week, even though the state asked for an immediate block. Judge David Joseph instead left the current rules in place and told the Food and Drug Administration to report back within six months on its safety review. (apnews.com) That means telehealth prescriptions and mail delivery of mifepristone still work the same way they did on April 7, 2026. The lawsuit is paused, not dead, and the judge signaled he may revisit the case if the agency does not move fast enough. (nhpr.org) The fight is about one drug and one set of federal safety rules. Mifepristone is the first pill in a two-drug regimen for ending an early pregnancy, and the Food and Drug Administration first approved it in September 2000. (fda.gov) The key rules are called a Risk Evaluation and Mitigation Strategy, which is the agency’s special rulebook for drugs it wants watched more closely. In January 2023, the Food and Drug Administration changed that rulebook so the old in-person dispensing requirement was removed and certified pharmacies could ship the drug by mail. (fda.gov) Louisiana says that 2023 change went too far because it lets pills cross state lines into places where abortion is banned. The state’s attorney general, Liz Murrill, tied the case to Louisiana resident Rosalie Markezich, who says her boyfriend obtained pills from California and gave them to her without her consent. (dailysignal.com) Judge Joseph did not give Louisiana the immediate win it wanted, but he did hand the state something important. He wrote that the challenge to mail distribution has standing and is likely to succeed on the merits, which is a strong signal about how he currently views the Food and Drug Administration’s 2023 policy. (dailysignal.com) That is why both sides claimed part of the ruling. Abortion-rights groups pointed to the unchanged access, while Louisiana pointed to the judge’s language about “irreparable harm” and said it will ask the United States Court of Appeals for the Fifth Circuit to vacate the 2023 rules while the case continues. (plannedparenthood.org) (dailysignal.com) This case lands after the United States Supreme Court already threw out an earlier mifepristone challenge in June 2024 because the anti-abortion doctors who sued could not show they were injured by the Food and Drug Administration’s actions. The Louisiana case is different because a state is now pressing the challenge and focusing on mail access and dispensing rules. (usnews.com) So the immediate answer is simple: nothing changes at the mailbox today. The bigger answer is that a federal court has now treated the Food and Drug Administration’s safety architecture around mifepristone as something judges may rework later, one dispensing rule at a time. (apnews.com) (nhpr.org)